| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.10. | Celldex Therapeutics' Barzolvolimab Meets Phase 2 Study Endpoints For Chronic Inducible Urticaria | 561 | AFX News | WASHINGTON (dpa-AFX) - Celldex Therapeutics Inc. (CLDX) announced that barzolvolimab met all primary and secondary endpoints with high statistical significance in a positive Phase 2 study targeting... ► Artikel lesen | |
| 27.10. | Novartis Announces Promising 12-Month Results For Fabhalta In C3 Glomerulopathy | 616 | AFX News | BASEL (dpa-AFX) - Novartis (NVS) presented 12-month data from the Phase III APPEAR-C3G study at the American Society of Nephrology or ASN Kidney Week 2024. The results showed that patients with... ► Artikel lesen | |
| 27.10. | Biogen's Phase 2 Study Shows Promising Results For Felzartamab In IgA Nephropathy | 581 | AFX News | WESTON (dpa-AFX) - Biogen Inc. (BIIB) announced that results from the Phase 2 IGNAZ study evaluating felzartamab, an investigational anti-CD38 monoclonal antibody, in individuals with IgA nephropathy... ► Artikel lesen |
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| TESLA | 549 |
| NVIDIA | 511 |
| LILIUM | 458 |
| NOVO NORDISK | 391 |
| BAYER | 372 |
| EVOTEC | 300 |
| BYD | 298 |
| TUI | 279 |
| PALANTIR TECHNOLOGIES | 263 |
| D-WAVE QUANTUM | 256 |
| VOLKSWAGEN | 240 |
| MICROSTRATEGY | 236 |
| NEL | 148 |
| RWE | 145 |
| AIXTRON SE | 144 |
| RHEINMETALL | 144 |
| XIAOMI | 139 |
| BASF | 137 |
| SUPER MICRO COMPUTER | 128 |
| AMAZON | 127 |
| ATOS | 127 |
| COMMERZBANK | 124 |
| DEUTSCHE TELEKOM | 119 |
| PLUG POWER | 119 |
| FREYR BATTERY | 114 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
